Abstract
Oxaliplatin (OXAL) is regarded as a platinum-based anti-neoplastic agent. However, its perturbations on membrane ionic currents in neurons and neuroendocrine or endocrine cells are largely unclear, though peripheral neuropathy has been noted during its long-term administration. In this study, we investigated how the presence of OXAL and other related compounds can interact with two types of inward currents; namely, hyperpolarization-activated cation current (Ih) and membrane electroporation-induced current (IMEP). OXAL increased the amplitude or activation rate constant of Ih in a concentration-dependent manner with effective EC50 or KD values of 3.2 or 6.4 μM, respectively, in pituitary GH3 cells. The stimulation by this agent of Ih could be attenuated by subsequent addition of ivabradine, protopine, or dexmedetomidine. Cell exposure to OXAL (3 μM) resulted in an approximately 11 mV rightward shift in Ih activation along the voltage axis with minimal changes in the gating charge of the curve. The exposure to OXAL also effected an elevation in area of the voltage-dependent hysteresis elicited by long-lasting triangular ramp. Additionally, its application resulted in an increase in the amplitude of IMEP elicited by large hyperpolarization in GH3 cells with an EC50 value of 1.3 μM. However, in the continued presence of OXAL, further addition of ivabradine, protopine, or dexmedetomidine always resulted in failure to attenuate the OXAL-induced increase of IMEP amplitude effectively. Averaged current-voltage relation of membrane electroporation-induced current (IMEP) was altered in the presence of OXAL. In pituitary R1220 cells, OXAL-stimulated Ih remained effective. In Rolf B1.T olfactory sensory neurons, this agent was also observed to increase IMEP in a concentration-dependent manner. In light of the findings from this study, OXAL-mediated increases of Ih and IMEP may coincide and then synergistically act to increase the amplitude of inward currents, raising the membrane excitability of electrically excitable cells, if similar in vivo findings occur.
Keywords: pituitary cell, olfactory neuron, hyperpolarization-activated cation current, membrane electroporation-induced current, oxaliplatin
1. Introduction
Oxaliplatin (OXAL, Eloxatin®) belongs to a family of platinum-based chemotherapeutic compounds. In combination with 5-fluorouracil, this drug has been ever-increasingly used in the treatment of advanced colorectal or gastric cancer [1,2,3]. Despite the good safety profile, its use has been well-established to confer susceptibility to peripheral neuropathy, affecting sensory and motor nerve fibers, explaining its unsuitability for long-term treatment [1,4,5,6,7,8,9,10]. However, the ionic mechanism of OXAL-induced actions through which it effects peripheral neuropathy still remains largely unanswered.
There is growing evidence to show that the neurotoxicity of OXAL is closely connected to its modulations on functional activities of different ionic channels present in the surface membrane of electrically excitable cells [7,11,12,13,14]. For example, OXAL has been demonstrated to suppress different types of voltage-gated K+ or Na+ currents in various preparations, such as myelinated axons, sciatic-nerve preparations, and motoneuron-like cells [11,13,14,15,16]. Of interest, this agent was also recently reported to activate Ih in isolated dorsal root ganglion neurons, and this action is thought to be implicated in its modifications of pain sensation [17,18,19,20].
Hyperpolarization-activated cation current (Ih) is a key determinant of repetitive electrical activity in heart cells, and in a variety of neurons, neuroendocrine, and endocrine cells [21,22,23,24,25,26,27]. This type of ionic current can conduct Na+ and K+ ions, and the current activation of its own accord can act to depolarize membrane potential, thereby adequately reaching the threshold required for action potential generation [22,28]. It is regarded to be carried by channels of the hyperpolarization-activated cyclic nucleotide-gated (HCN) gene family, named HCN1, HCN2, HCN3, and HCN4 [28]. Generation of HCN1-, HCN2-, and HCN4-deficient mice has highlighted the important role of these channels in regulation of pacemaker activity [26,29]. Of interest, previous reports have shown the ability of either MEL55A, an inhibitor of Ih, or dexmedetomidine to ameliorate OXAL-induced pain sensation [18,19,30].
Membrane electroporation (MEP) applies an external electrical field to effect a considerable increase in the electrical conductivity and permeability of the plasma membrane [31,32,33]. Such a maneuver has been tailored to electrotransfer membrane-impermeant molecules, including DNAs, anti-neoplastic drugs, and antibodies, into cells’ interiors. Specifically, by applying an electrical field to the cells that just surpasses the capacitance of cell membrane, the membrane transiently becomes destabilized and permeable. Consequently, different substances can readily enter the cell. Notably, MEP-induced current (IMEP) combined with antineoplastic agents has been increasingly considered as a new therapeutic maneuver for facilitating the uptake of chemotherapeutic agents that do not easily cross the cell membrane and for the treatment of internal tumors [34,35]. However, few studies have investigated the OXAL effect on IMEP.
A recent report showed the ability of OXAL administration to elevate serum prolactin level [36]. OXAL was also reported to disrupt the endocrine axis of ACTH-cortisol and renin-angiotensin-aldosterone [37]. The treatment of OXAL is also likely to alter the functional activity of endocrine cells, including pituitary cells. However, how this compound interacts with membrane ion channels in endocrine cells remains largely unknown.
Therefore, in this study we tried to explore the effect of OXAL or other related compounds on ionic currents (e.g., Ih and IMEP) in pituitary tumor (GH3) cells. Whether the IMEP in olfactory ensheathing (Rolf T1.B) cells is subject to be perturbed by OXAL was also examined. Our findings revealed that OXAL is able to stimulate both Ih and IMEP with similar potency, which will summate to affect electrical behaviors of electrically excitable cells. These stimulatory effects presented herein tend to be acute in onset and are not thought to be mediated through the formation of platinum-DNA adducts, and they might conceivably account for pharmacological or toxicological actions of OXAL occurring in vivo.
2. Results
2.1. The Effect of OXAL on the Amplitude and Kinetics of Hyperpolarization-Activated Cation Current (Ih) Recorded from GH3 Cells
In the first stage of whole-cell voltage-clamp current recordings, we explored if OXAL had any perturbations on Ih in these cells. Cells were bathed in Ca2+-free Tyrode’s solution and the recording pipette was filled with K+-containing solution. The compositions of these solutions are described in Materials and Methods. The purpose for using Ca2+-free solution in our whole-cell recordings was to avoid possible modifications by extracellular Ca2+ of Ih. As shown in Figure 1Aa, upon membrane hyperpolarization from −40 to −100 mV with a duration of 2 s, the cation inward current with a slowly activating time course was readily evoked. This type of hyperpolarization-activated current was sensitive to inhibition by CsCl, tramadol, and ivabradine. In agreement with previous studies described in different types of neurons, and neuroendocrine or endocrine cells, it was hence identified as an Ih [24,27,38,39]. Of interest, addition of OXAL immediately led to an increase in the amplitude of Ih in these cells. For example, as cells were exposed to 3 μM OXAL, current amplitude at the level of −100 mV significantly increased from 109 ± 18 to 168 ± 27 pA (n = 8, p < 0.05). After washout of the agent, current amplitude returned to 113 ± 22 pA (n = 7, p < 0.05).
Apart from its reduction in Ih amplitude, the time course of Ih activation during the 2 s membrane hyperpolarization from −40 to −100 mV was noted to decrease in the presence of OXAL (Figure 1Ab). For example, addition of 3 μM OXAL produced a significant shortening of activation time constant (τ) of Ih from 648 ± 24 to 581 ± 21 ms (n = 8, p < 0.05). In an attempt to evaluate quantitative estimate of OXAL-mediated stimulation of Ih, the values of activation time constants of Ih observed in these cells were further analyzed. The time courses for Ih activation in the presence of different OXAL concentrations were fitted using a single-exponential function by virtue of least-squares minimization procedure. The concentration dependence of Ih activation during long-step hyperpolarizing pulse is illustrated in Figure 1B. It is evident from the present observations that cell exposure to OXAL led to a concentration-dependent increase in the rate constant (i.e., 1/τ) of Ih activation by membrane hyperpolarization. It was also observed to display a linear relationship between 1/τ and the OXAL concentration with a correlation coefficient of 0.95 (Figure 1B). The forward and backward rate constants from minimum kinetic scheme detailed above in Materials and Methods were then derived and estimated to be 0.236 s−1μM−1 and 1.528 s−1, respectively; thereafter, the value of the dissociation constant (KD = k−1/k+1*) turned out to be 6.47 μM. Moreover, the concentration-dependent effect of OXAL on Ih amplitude measured at the end of 2 s hyperpolarizing pulse was constructed and plotted (Figure 1C). The EC50 value required for OXAL-mediated stimulation of Ih seen in GH3 cells was calculated to be 3.2 μM, a value which is similar to the KD value analyzed on the basis of the first-order reaction scheme.
2.2. Comparisons of the Effects of OXAL, OXAL Plus Ivabradine, OXAL Plus Protopine, and OXAL Plus Dexmedetomidine on Ih Amplitude
We further examined the effects of OXAL, protopine, demedetomidine, OXAL plus ivabradine, OXAL plus protopine, and OXAL plus dexmedetomidine on the amplitude of Ih in GH3 cells. Similar to the OXAL action, addition of protopine (3 μM) or dexmedetomidine (3 μM) alone could suppress Ih amplitude by 69% and 73%, respectively. As depicted in Figure 2, still in the presence of 3 μM OXAL, subsequent addition of either ivabradine (3 μM), protopine (10 μM), and dexmedetomidine (3 μM) could effectively attenuate OXAL-mediated stimulation of Ih elicited by long-lasting membrane hyperpolarization. Ivabradine is an inhibitor of Ih [28,40], dexmedetomidine was previously observed to induce analgesia through a mechanism linked to the inhibition of Ih [30], and protopine was reported to suppress multiple types of ionic currents [41]. The experimental observations indicate that further addition of either ivabradine, protopine, or dexmedetomidine could attenuate OXAL-mediated increase in Ih amplitude identified in GH3 cells, and that the addition of protopine or dexmedetomidine alone was able to suppress Ih.
2.3. The Effect of OXAL on the Current versus Voltage (I–V) Relationship of Ih
The effects of OXAL on Ih measured at a family of hyperpolarizing steps was further studied. The averaged I–V relationships of Ih measured at the end of hyperpolarizing pulses in the control and during the exposure to 3 μM OXAL are illustrated in Figure 3A,B. Notably, from these I–V curves of the current, during the exposure to 3 μM OXAL, the macroscopic Ih conductance measured at the end of voltage steps ranging between −80 and −130 mV was significantly increased to 2.06 ± 0.05 nS (n = 8, p < 0.05) from a control value of 2.87 ± 0.08 nS (n = 8).
2.4. The Effect of OXAL on the Steady-State Activation Curve of Ih
To characterize the inhibitory effect of OXAL on Ih, we also tested if the exposure to this drug might result in the modifications on the steady-state activation curve of Ih in GH3 cells. Figure 3C illustrates the activation curve of Ih obtained in the absence and presence of OXAL (3 μM). Furthermore, as shown in Figure 3D, the Ih trajectories evoked in response to a 1 s downslope ramp from −40 to −150 mV with and without addition of 3 μM OXAL were examined. The observations were quite indistinguishable from the experimental results derived from those elicited by a family of maintained rectangular pulses (Figure 3B). It is, therefore, evident from the present data that the presence of OXAL exerts stimulatory action on the amplitude and gating of Ih during long-lasting membrane hyperpolarizations.
2.5. The Effect of OXAL on Voltage-Dependent Hysteresis of Ih Elicited in Response to a Long-Lasting Triangular Ramp Pulse
The voltage-dependent hysteresis of Ih has been previously demonstrated to exert a high influence on electrical behaviors such as action potential (AP) firing [42,43,44]. For this reason, we further explored whether there is possible voltage-dependent hysteresis existing in Ih recorded from GH3 cells. In this set of experiments, we exploited a long-lasting triangular ramp pulse with a duration (i.e., 0.11 V/s) for measurement of the hysteretic properties, as whole-cell configuration was established. It is evident from Figure 4A that the trajectory of Ih elicited by the upsloping (i.e., depolarization from −150 to −40 mV) and downsloping (hyperpolarization from −40 to −150 mV) ramp pulse as a function of time was virtually distinguishable between these two limbs. The current amplitude elicited during the upsloping limb of triangular voltage ramp was higher than that by the downsloping limb; that is, there is a voltage-dependent hysteresis for this current; namely, the relationship of Ih versus membrane potential. As the ramp speed became reduced, the hysteresis degree for Ih was progressively raised. Of interest, as the examined cell was exposed to OXAL (3 μM), Ih amplitude evoked in the upsloping limb of long-lasting triangular ramp was observed to increase to a greater extent than that measured from the downsloping limb. For example, in controls, Ih values at the level of −110 mV elicited during the upsloping and downsloping limbs of triangular ramp pulse were measured to be 186 ± 19 and 123 ± 12 pA (n = 9), respectively, the values of which were found to differ significantly (p < 0.05). Specifically, as cells were exposed to 3 μM OXAL, the amplitudes of triangular ramp-induced forward and backward Ih taken at the same level of membrane potential were significantly raised to 236 ± 23 and 156 ± 17 pA (n = 9, p < 0.05), respectively.
We next quantified the degree of voltage-dependent hysteresis on the basis of the differences in areas under the curves (indicated in shaded area) in the forward (upsloping) and reverse (downsloping) directions, as described by the arrows in Figure 4B. It was seen that for Ih in GH3 cells, the degree of voltage hysteresis increased with slower ramp speed, and that the presence of DEX led to a conceivable reduction in the amount of such hysteresis. Figure 4B illustrates a summary of the data showing the effects of OXAL and OXAL plus ivabradine on the hysteretic area under the curve between forward and backward current traces. For example, except for the increase of Ih magnitude, addition of OXAL (3 μM) significantly elevated the area by about 1.8 fold, elicited in response to such a long-lasting triangular voltage ramp; moreover, the subsequent application of 3 μM ivabradine significantly decreased area by 60%.
2.6. The Effect of OXAL on Membrane Electroporation-Induced Current (IMEP) in GH3 Cells
Previous studies have demonstrated the presence of IMEP elicited by large membrane hyperpolarization in different types of cells [31,32,33,45,46]. In another series of experiments, we raised the question of whether the presence of OXAL has possible modifications on this type of ionic current. We bathed cells in Ca2+-free Tyrode’s solution, and whole-cell current recordings were performed. As described in previous studies [31,45,46], when the cell was maintained at −80 mV, the hyperpolarizing pulse from −80 to −200 mV with a duration of 300 ms was applied to evoke IMEP. As shown in Figure 5A, as cells were exposed to OXAL, the amplitude of IMEP was progressively enhanced. For example, at the level of −200 mV, the presence of 3 μM OXAL significantly increased IMEP amplitude from 307 ± 18 to 716 ± 67 pA (n = 9, p < 0.05). After washout of the agent, current amplitude returned to 317 ± 23 pA (n = 7, p < 0.05). When K+ in the pipette solution was replaced with equimolar concentration of NMDG+, this current could still be induced by addition of 3 μM OXAL, although current amplitude was relatively smaller.
The relationship between the OXAL concentration and the percentage increase of IMEP was constructed (Figure 5B). The half-maximal concentration required for its stimulation of IMEP was estimated to be 1.3 μM. However, in the continued presence of 3 μM OXAL, subsequent addition of ivabradine (3 μM), protopine (10 μM), or dexmedetomidine (3 μM) was observed to fail to attenuate its stimulation of IMEP (Figure 5C). Conversely, further addition of LaCl3 (10 μM) reversed OXAL-induced increase in IMEP, as evidenced by a significant reduction of IMEP to 412 ± 34 pA (n = 8, p < 0.05).
The averaged I–V relationship of IMEP with or without addition of OXAL is illustrated in Figure 5D. Notably, following the application of 3 μM OXAL, the amplitude of IMEP elicited in response to membrane hyperpolarization was increased throughout the entire voltage-clamp steps examined. The threshold for elicitation of IMEP in the control was observed to be around −100 mV, while that for current elicitation during cell exposure to 3 μM OXAL became depolarized to −80 mV. Moreover, cell exposure to OXAL (3 μM) significantly raised the slope of the linear fit of IMEP measured at the voltages between −120 and −200 mV from 2.96 ± 0.13 to 5.75 ± 0.32 nS (n = 8, p < 0.05). Therefore, as GH3 cells were continuously exposed to OXAL, the I–V relationship of hyperpolarization-induced IMEP can be modified.
2.7. The Stimulatory Effect of OXAL on Ih in Pituitary R1220 Cells
We further wanted to test if Ih in other types of endocrine pituitary cells (e.g., pituitary R1220 cells) could be perturbed by OXAL. This type of rat pituitary cell was originally from neonatal, day-8 rats and cryopreserved in primary cultures [47]. As illustrated in Figure 6, within 2 min of exposing cells to OXAL (1 μM), the Ih amplitude during hyperpolarizing step was progressively increased, in combination with an increase in activation rate of this current. The presence of 1 μM OXAL increased current amplitude from 299 ± 13 to 366 ± 18 pA (n = 7, p < 0.05). Moreover, in the continued presence of OXAL, subsequent addition of ivabradine (3 μM) was able to attenuate OXAL-induced inhibition of Ih, as evidenced by the reversal of Ih amplitude to 312 ± 15 pA (n = 7, p < 0.05). These experimental results reflect that the OXAL-mediated stimulation of Ih in this type of pituitary cell is indistinguishable from that mentioned above in GH3 cells.
2.8. Stimulatory Effect of OXAL on IMEP Identified in Rolf B1.T Cells
In a final set of recordings, we further examined if the presence of OXAL could cause any effects on IMEP inherently in Rolf B1.T cells. The results showed that addition of OXAL effectively increased IMEP in a concentration-dependent manner (Figure 7A). For example, as cells were exposed to 3 μM OXAL, the current measured at the level of −200 mV was significantly raised to 1102 ± 185 pA from a control of 192 ± 32 pA (n = 9, p < 0.01). Moreover, as shown in Figure 7B, subsequent addition of LaCl3 (10 μM), still in the presence of 3 μM OXAL, was effective at attenuating OXAL-mediated increase of IMEP amplitude, although the inability of ivabradine to alter its stimulation of IMEP was demonstrated in these cells. It is clear from the results that the biophysical or pharmacological properties of IMEP are virtually distinguishable from those of Ih, despite the ability of both currents to be elicited by membrane hyperpolarizations. Additionally, in accordance with the experimental observations described above in GH3 cells, OXAL was effective at increasing IMEP identified in this type of olfactory neuron.
3. Discussion
The present study provides us with evidence showing that the presence of OXAL is able to exert dual stimulatory actions on two types of ionic currents—Ih and IMEP. It is important to note that the OXAL concentration used in this study is closely similar to that achieved in the plasma of treated patients (i.e., 3.6–5.6 μM) [48]. The stimulation by this agent of Ih seen in GH3 cells was not instantaneous and occurred in a time and concentration-dependent fashion, although the KD value (i.e., 6.4 μM) for the stimulation of Ih tends to be greater than EC50 value (i.e., 3.2 μM) for its increase of Ih amplitude. Therefore, any perturbations of Ih or IMEP induced by OXAL depend not simply on the OXAL concentration, but also on different factors, such as membrane potential, intracellular Ca2+ concentration, and cell volume.
In accordance with earlier studies [24,27,38,39], the present results demonstrated that pituitary GH3 and R1220 cells could functionally express a hyperpolarization-activated cation currents recognized as Ih. There are four mammalian subtypes (HCN1, HCN2, HCN3, and HCN4) which have been cloned to date [43,49,50]. It has been demonstrated that different HCN isoforms might combine to constitute macroscopic Ih existing in different types of neurons and endocrine or neuroendocrine cells [25,38,50]. As HCN2, HCN3, or mixed HCN2 + HCN3 channels are functionally expressed in GH3 cells [24], OXAL-induced stimulation of Ih in native cells does not tend to be isoform specific, although our experimental results showed that OXAL could modify the amplitude and gating of Ih in GH3 and R1220 cells. Because of the importance of Ih (i.e., HCNx-encoded currents) in contributing to excitability and automaticity of electrically excitable cells [18,22,28,38,40,50], findings from the present results could provide novel insights into electrophysiological and pharmacological properties of OXAL or other structurally related compounds [19,20].
Previous studies have demonstrated the ability of OXAL to stimulate transient receptor potential (TRP) ankyrin channels, the activity of which could be linked to nerve injury [51]. One might thus expect that the TRP superfamily of cation channels in GH3 cells could be elicited by the presence of OXAL. The earlier studies have reported the presence of IMEP in response to membrane hyperpolarization in a variety of cells including GH3 cells [32,33,45,46]. It is important to note that, being distinguishable from those of Ih [23,28,49], the biophysical properties of macroscopic IMEP exhibit themselves as virtually stochastic, but obviously not deterministic, together with variable activation time course elicited by membrane hyperpolarization [31,45,46]. Therefore, it seems unlikely that IMEP stimulated by OXAL seems unlikely to be mediated by the activity of TRP or TRP-like channels.
The present observations led us to speculate that stimulation of both Ih and IMEP caused by OXAL may account significantly for its neurological or adverse reactions [4,5,52]. A previous report showed that HCN2 is elevated after oxaliplatin-induced neuropathic pain and that HCN2-mediated pain might be mediated through the upregulation of NR2B and the activation of the CaMKII/CREB cascade in spinal neurons [19]. The effects of OXAL on membrane ionic currents described herein were noted to be rapid in onset, and they should be upstream of the formation of platinum-DNA adducts occurring inside the nucleus [4,52].
Previous studies have shown that conventional MEP might be sufficiently large to porate cytoplasmic organelles inside the cell [53]. LaCl3 was reported to prevent the mitochondrial morphology transition induced by chemical injury with reactive oxygen species in Arabidopsis [54]. It is important to speculate that OXAL-induced stimulation of MEP-induced channels presented herein contributes to its activation of mitochondrial permeability transition pore. Our results are in parallel with a scenario showing the role of mitochondrial mechanism in platinum-induced peripheral neuropathy [55,56]. It remains to be studied to what extent the presence of OXAL can enhance MEP-elicited channels which indirectly activate the intrinsic pathway to apoptotic or necrotic changes by inducing change in mitochondrial permeability transition pore.
Voltage-dependent hysteresis of Ih is thought to exhibit a substantial role in influencing the electrical behavior of electrically excitable cells such as GH3 cells. In agreement with previous observations [42,43,44], the Ih natively existing in GH3 cells was described to undergo either a hysteretic change in its voltage dependence, or a mode shift in which the voltage sensitivity in gating charge movements of the current depends on the previous state of the channel [42,43]. In this study, we also examined the possible perturbations of OXAL on such a non-equilibrium property of Ih in GH3 cells. Our results clearly demonstrated that the presence of this agent was capable of enlarging such hysteresis involved in the voltage-dependent elicitation of Ih. However, further application of ivabradine, still in the presence of OXAL, could attenuate OXAL-mediated increase in the area of voltage-dependent hysteresis.
Membrane hyperpolarization was not produced by the operation of delayed-rectifier K+ currents and voltage-gated Na+ currents. However, from a model nerve cell system, a recent report showed the presence of hyperpolarization-mediated change in the conduction during action potential firing [57], suggesting that either Ih, IMEP or both in response to membrane hyperpolarization might have the propensity to perturb the conduction along the axon during electrical firing. In this study we were unable to observe suppressive effect of OXAL (3 μM) on proliferating GH3 cells. OXAL-mediated stimulation of Ih or IMEP might not be linked to its suppression of cell growth. In pituitary R1220 cells, which have been cryopreserved in primary cultures, the presence of OXAL was also capable of increasing Ih amplitude and further addition of ivabradine reversed its stimulation of this current. Therefore, the GH3 cells are not the only anterior pituitary cell types to functionally express HCN channels [25,38]. However, it would be worthwhile to explore whether OXAL-mediated stimulatory effects on Ih or IMEP could differentially occur in pituitary tumor (GH3) cells and in freshly isolated pituitary lactotrophs. Further studies focusing on different cell hosts, including human pituitary cells, will be required. Also, varying cellular environments to distinguish the behavior of normal cells from tumor cells will shed the light to the avidity of oxaliplatin and its interactive modes through which it exerts the effects on Ih and IMEP.
In agreement with several studies [7,11,13,15,16], the OXAL action in vivo is not exclusively connected to the formation of platinum-DNA adducts [4,52]. Collectively, the experimental results presented herein led us to propose that the perturbation by OXAL of Ih and IMEP (Figure 8) is another intriguing mechanism, through the ability of it and other structurally related compounds to interfere with cell behaviors, particularly in electrically excitable cells [51], if similar in vivo findings occur.
4. Materials and Methods
4.1. Chemicals, Drugs, and Solutions
Oxaliplatin (OXAL; Eloxatin®, trans-1-diaminocyclohexane oxaliplatinum, C8H14N2O4Pt, (PubChem CID: 43805)) was acquired from Sanofi-Aventis (New York, NY, USA); ivabradine, protopine (4,6,7,14-tetrahydro-5-methylbis[1,3]benzodioxolo[4,5-c:5′,6′-g]azecin-13(5H)-one) was from Sigma-Aldrich (St. Louis, MO, USA); and dexmedetomidine (DEX) was from Abbott Laboratories (Abbott Park, IL, USA). All culture media, horse serum, fetal calf or bovine serum, L-glutamine, and trypsin/EDTA were obtained from Invitrogen (Carlsbad, CA, USA), unless otherwise indicated, while other chemicals, including EGTA, HEPES, LaCl3, aspartic acid, and N-methyl-D-glucamine+ (NMDG+), were of the highest purity and analytical grade.
The composition of normal Tyrode’s solution used in this study was as follows (in mM): NaCl 136.5, KCl 5.4, CaCl2 1.8, MgCl2 0.53, glucose 5.5, and HEPES-NaOH buffer 5.5 (pH 7.4). To record Ih or IMEP, we filled the patch electrode with the following solution (composition in mM): K-aspartate 130, KCl 20, KH2PO4 1, MgCl2 1, Na2ATP 3, Na2GTP 0.1, EGTA 0.1, and HEPES-KOH buffer 5 (pH 7.2). The medium or solution was commonly filtered using a 0.22 μm pore filter.
4.2. Cell Preparations
GH3 pituitary tumor cells, acquired from the Bioresources Collection and Research Center ((BCRC-6005); Hsinchu, Taiwan), were maintained in Ham’s F-12 medium supplemented with 15% horse serum (v/v), 2.5% fetal calf serum (v/v), and 2 mM L-glutamine in a humidified environment of 5% CO2/95% air. The clonal strain Rolf B1.T cell line was acquired from Sigma-Aldrich (lot number 03071601; St. Louis, MO, USA). This cell line was originally isolated from cultures of adult rat olfactory nerve cells. Cells have an antigenic phenotype which closely resembles that of olfactory ensheathing cells [58,59]. Rolf B1.T cells were grown in Dulbecco’s modified Eagle’s medium (Invitrogen, Carlsbad, CA, USA) supplemented with 2 mM L-glutamine and 10% fetal bovine serum (v/v). Rat pituitary cells (number R1220), which were originally isolated from neonate day-8 rats, were acquired from ScienCell Research Laboratories, Inc. (Excel Biomedical, Taipei, Taiwan), and they were grown in Epithelial Cell Medium (number 4101; ScienCell) [47,58,59]. The culture medium was refreshed every 2–3 days and cells underwent passaged when they reached confluence. Cell viability was assessed by the methylthiazole tetrazolium (MTT) salt assay. The experiments were commonly performed after 5 or 6 days of subcultivation (60–80% confluence).
4.3. Electrophysiological Measurements
Shortly before the experiments, cells were harvested and an aliquot of cell suspension was transferred to a home-made recording chamber mounted on the fixed stage of CKX-41 inverted microscope (Olympus, Tokyo, Japan). Cells were bathed at room temperature (20–25 °C) in normal Tyrode’s solution, the composition of which was indicated above. The recording electrodes were made of Kimax-51 glass capillaries (Kimble, Vineland, NJ, USA) by using either a PP-83 vertical puller (Narishige, Tokyo, Japan) or a P-97 Flaming/Brown horizontal puller, and their tips were then fire-polished with an MF-83 microforge (Narishige; London, UK). The electrodes used had a resistance of 3–5 MΩ and were filled with different internal solutions as detailed above. Patch-clamp whole cell recordings were performed at room temperature in standard patch-clamp technique by use of either an RK-400 amplifier (Bio-Logic, Claix, France), or an amplifier of Axopatch-200B or Axoclamp-2B (Molecular Devices, Sunnyvale, CA, USA). The junction potential between the pipette and bath solution was nulled after the pipette entered the bath but immediately before seal formation was made, and whole-cell data were hence corrected.
4.4. Data Recordings and Analyses
The signals, consisting of potential and current traces, were stored online on an ASUS VivoBook Flip-14 touchscreen laptop computer (TP412U; Taipei, Taiwan) at 10 kHz through a Digidata 1440A interface (Molecular Devices, Sunnyvale, CA, USA). During the experiments, the latter device was controlled by pCLAMP 10.7 (Molecular Devices). Current signals were low-pass filtered at 3 kHz with an FL-4 four-pole Bessel filter (Dagan, Minneapolis, MN, USA). The data were analyzed offline using either pCLAMP 10.7 (Molecular Devices), OriginPro (OriginLab, Northampton, MA, USA), or various custom-made macros created from Microsoft ExcelTM 2019.
To assess percentage increase (i.e., y) of OXAL on the stimulation of Ih or IMEP, the OXAL concentration required to increase 50% of current amplitude was determined using a modified Hill function in the following form:
(1) |
where [OXAL] denotes the OXAL concentration applied; nH is the Hill coefficient; EC50 is the concentration required for a 50% increase, and Emax is the OXAL-maximal mediated increase in Ih or IMAP. Current amplitude during cell exposure to 100 μM OXAL was taken as 100%, and those at various concentrations of OXAL were analyzed and then compared.
The stimulatory effect of OXAL on Ih measured from GH3 cells is explained by using a state-dependent stimulator that preferentially binds to the open state of the HCN channel. A minimal first-order kinetic scheme was derived as follows:
(2) |
where [OXAL] is the OXAL concentration; α and β are the voltage-gated rate constants for the opening and closing of the HCN channel, respectively; k+1* and k-1 are the rate constants used for forward and backward reaction by OXAL; and C, O, and O·OXAL indicate the closed, open, and open-bound state, respectively.
The forward (i.e., on) and reverse (i.e., off) rate constants, k+1* and k−1, were determined from the activation time constants (τ) of Ih obtained during cell exposure to different OXAL concentrations. From the first-order reaction scheme, the rate constants collected could then be assessed using an equation of the form:
(3) |
where k+1* or k−1 was respectively derived from the slope or from y-axis intercept at x-coordinate = 0 (i.e., [OXAL] = 0) of a linear function interpolating the reciprocal time constants (1/τ) with respect to the OXAL concentration (i.e., [OXAL]).
To characterize the stimulatory effects of OXAL on Ih, the steady-state activation curve of the current with respect to command potential was constructed and compared. The relationships between the membrane potentials and the normalized amplitudes of Ih with and without addition of 3 μM OXAL were least-squares fitted with a Boltzmann function written as:
(4) |
where Imax denotes the maximal activated Ih or IMEP; V is the potential in mV; V1/2 is the membrane potential for half-maximal activation; q is the apparent gating charge; and F, R, and T is Faraday’s constant, the universal gas constant, and the absolute temperature, respectively.
4.5. Statistical Analyses
Curve parameter estimation was performed by a nonlinear or linear, least-squares fitting routine. We made assertions about the variability of means that could be collected from a random cohort derived from the population concerned; therefore, the standard error could have been more appropriate than the standard deviation. Data were hence presented as the means ± standard errors of the means (SEMs), with sample sizes (n) which indicate the number of cells collected to analyze the results, and error bars were plotted as SEMs. The paired or unpaired Student’s t-test or a one-way analysis of variance (ANOVA) followed by post-hoc Fisher’s least-significance difference test for multiple comparisons, were implemented for statistical analyses. The nonparametric Kruskal–Wallis test was, however, utilized, if normality underlying ANOVA tended to be violated. A probability level of <0.05 was used to define significance.
Acknowledgments
The authors are indebted to Kaisen Lee for contributing to the earlier experiments in this study. The authors are grateful to some important comments from Li-Tzong Chen, National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan.
Author Contributions
S.-N.W. was responsible for the study design. Z.-H.G., S.-W.L. and S.-N.W. were involved in conducting the experiments. W.-T.C. and S.-N.W. wrote the manuscript with editing help from all co-authors. P.-Y.L. and Y.-C.L. supervised. All authors have read and agreed to the published version of the manuscript.
Funding
This study was financially supported by the grants from National Cheng Kung University (D106-35A13, D107-F2519 and NCKUH-10709001), and from Ministry of Science and Technology (MOST-108-2314-B-006-094).
Conflicts of Interest
The authors declare no conflict of interest.
References
- 1.Graham J., Mushin M., Kirkpatrick P. Oxaliplatin. Nat. Rev. Drug Discov. 2004;3:11–12. doi: 10.1038/nrd1287. [DOI] [PubMed] [Google Scholar]
- 2.Chen C.C., Chen L.T., Tsou T.C., Pan W.Y., Kuo C.C., Liu J.F., Yeh S.C., Tsai F.Y., Hsieh H.P., Chang J.Y. Combined modalities of resistance in an oxaliplatin-resistant human gastric cancer cell line with enhanced sensitivity to 5-fluouracil. Br. J. Cancer. 2007;97:334–344. doi: 10.1038/sj.bjc.6603866. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Zhang F., Zhang Y., Jia Z., Wu H., Gu K. Oxaliplatin-based regimen is superior to cisplatin-based regimen in tumour remission as first-line chemotherapy for advanced gastric cancer: A meta-analysis. J. Cancer. 2019;10:1923–1929. doi: 10.7150/jca.28896. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Hartmann J.T., Lipp H.P. Toxicity of platinum compounds. Expert Opin. Pharmacother. 2003;4:889–901. doi: 10.1517/14656566.4.6.889. [DOI] [PubMed] [Google Scholar]
- 5.Kanat O., Ertas H., Caner B. Platinum-induced neurotoxicity: A review of possible mechanisms. World J. Clin. Oncol. 2017;8:329–335. doi: 10.5306/wjco.v8.i4.329. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Sereno M., Gutiérrez-Gutiérrez G., Rubio J.M., Apellániz-Ruiz M., Sánchez-Barroso L., Casado E., Falagan S., López-Gómez M., Merino M., Gómez-Raposo C., et al. Genetic polymorphisms of SCN9A are associated with oxaliplatin-induced neuropathy. BMC Cancer. 2017;17:63. doi: 10.1186/s12885-016-3031-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Gebremedhn E.G., Shortland P.J., Mahns D.A. The incidence of acute oxaliplatin-induced neuropathy and its impact on treatment in the first cycle: A systemic review. BMC Cancer. 2018;18:410. doi: 10.1186/s12885-018-4185-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Xiao X., Oswald J.T., Wang T., Zhang W., Li W. Use of anticancer platinum compounds in combination therapies and challenges in drug delivery. Curr. Med. Chem. 2018 doi: 10.2174/0929867325666181105115849. [DOI] [PubMed] [Google Scholar]
- 9.Alberti P. Platinum-drugs induced peripheral neurotoxicity: Clinical course and preclinical evidence. Exp. Opin. Drug Metab. Toxicol. 2019;15:487–497. doi: 10.1080/17425255.2019.1622679. [DOI] [PubMed] [Google Scholar]
- 10.Valentine W.M. Toxic peripheral neuropathies: Agents and mechanisms. Toxicol. Pathol. 2019 doi: 10.1177/0192623319854326. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Wu S.N., Chen B.S., Wu Y.H., Peng H., Chen L.T. The mechanism of the actions of oxaliplatin on ion currents and action potentials in differentiated NG108-15 neuronal cells. Neurotoxicology. 2009;30:677–685. doi: 10.1016/j.neuro.2009.04.010. [DOI] [PubMed] [Google Scholar]
- 12.Huang M.H., Huang Y.M., Wu S.N. The inhibition by oxaliplatin, a platinum-based anti-neoplastic agent, of the activity of intermediate-conductance Ca2+-activated K+ channels in human glioma cells. Cell. Physiol. Biochem. 2015;37:1390–1406. doi: 10.1159/000430404. [DOI] [PubMed] [Google Scholar]
- 13.Aromolaran K.A., Goldstein P.A. Ion channels and neuronal hyperexcitability in chemotherapy-induced peripheral neuropathy: Cause and effect? Mol. Pain. 2017;13:1744806917714693. doi: 10.1177/1744806917714693. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Anon B., Largeau B., Girault A., Chantome A., Caulet M., Perray C., Moussata D., Vandier C., Barin-Le Guellec C., Lecomte T. Possible association of CAG repeat polymorphism in KCNN3 encoding the potassium channel SK3 with oxaliplatin-induced neurotoxicity. Cancer Chemother. Pharmacol. 2018;82:149–157. doi: 10.1007/s00280-018-3600-1. [DOI] [PubMed] [Google Scholar]
- 15.Benoit E., Brienza S., Dubois J.M. Oxaliplatin, an anticancer agent that affects both Na+ and K+ channels in frog peripheral myelinated axons. Gen. Physiol. Biophys. 2006;25:263–276. [PubMed] [Google Scholar]
- 16.Kagiava A., Tsingotjidou A., Emmanouilides C., Theophilidis G. The effects of oxaliplatin, an anticancer drug, on potassium channels of the peripheral myelinated nerve fibres of the adult rats. Neurotoxicology. 2008;29:1100–1106. doi: 10.1016/j.neuro.2008.09.005. [DOI] [PubMed] [Google Scholar]
- 17.Descoeur J., Pereira V., Pizzoccaro A., Francois A., Ling B., Maffre V., Couette B., Busserolles J., Courteix C., Noel J., et al. Oxaliplatin-induced cold hypersensitivity is due to remodeling of ion channel expression in nociceptors. EMBO Mol. Med. 2011;3:266–278. doi: 10.1002/emmm.201100134. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Dini L., Del Lungo M., Resta F., Melchiorre M., Spinelli V., Di Cesare Mannelli L., Ghelardini C., Laurino A., Sartiani L., Coppini R., et al. Selective blockade of HCN1/HCN2 channels as a potential pharmacological strategy against pain. Front. Pharmacol. 2018;9:1252. doi: 10.3389/fphar.2018.01252. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Liu X., Zhang L., Jin L., Tan Y., Li W., Tang J. HCN2 contributes to oxaliplatin-induced neuropathic pain through activation of the CaMKII/CREB cascade in spinal neurons. Mol. Pain. 2018;14:1–8. doi: 10.1177/1744806918778490. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Resta F., Micheli L., Laurino A., Spinelli V., Mello T., Sartiani L., Di Cesare Mannelli L., Cerbai E., Ghelardini C., Romanelli M.N., et al. Selective HCN1 block as a strategy to control oxaliplatin-induced neuropathy. Neuropharmacology. 2018;131:403–413. doi: 10.1016/j.neuropharm.2018.01.014. [DOI] [PubMed] [Google Scholar]
- 21.Belardinelli L., Giles W.R., West A. Ionic mechanisms of adenosine actions in pacemaker cells from rabbit heart. J. Physiol. 1988;405:615–633. doi: 10.1113/jphysiol.1988.sp017352. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Irisawa H., Brown H.F., Giles W. Cardiac pacemaking in the sinoatrial node. Physiol. Rev. 1993;73:197–227. doi: 10.1152/physrev.1993.73.1.197. [DOI] [PubMed] [Google Scholar]
- 23.Fu X.W., Brezden B.L., Wu S.H. Hyperpolarization-activated inward current in neurons of the rat’s dorsal nucleus of the lateral lemniscus in vitro. J. Neurophysiol. 1997;78:2235–2245. doi: 10.1152/jn.1997.78.5.2235. [DOI] [PubMed] [Google Scholar]
- 24.Liu Y.C., Wang Y.J., Wu P.Y., Wu S.N. Tramadol-induced block of hyperpolarization-activated cation current in rat pituitary lactotrophs. Naunyn Schmiedbergs Arch. Pharmacol. 2009;379:127–135. doi: 10.1007/s00210-008-0353-0. [DOI] [PubMed] [Google Scholar]
- 25.Kretschmannova K., Kucka M., Gonzalez-Iglesias A.E., Stojilkovic S.S. The expression and role of hyperpolarization-activated cyclic nucleotide-gated channels in endocrine anterior pituitary cells. Mol. Endocrinol. 2012;26:153–164. doi: 10.1210/me.2011-1207. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Datunashvili M., Chaudhary R., Zobeiri M., Luttjohann A., Mergia E., Baumann A., Balfanz S., Budde B., van Luijtelaar G., Pape H.C., et al. Modulation of hyperpolarization-activated inward current and thalamic activity modes by different cyclic nucleotides. Front. Cell. Neurosci. 2018;12:369. doi: 10.3389/fncel.2018.00369. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Hsiao H.T., Liu Y.C., Liu P.Y., Wu S.N. Concerted suppression of Ih and activation of IK(M) by ivabradine, an HCN-channel inhibitor, in pituitary cells and hippocampal neurons. Brain Res. Bull. 2019;149:11–20. doi: 10.1016/j.brainresbull.2019.03.016. [DOI] [PubMed] [Google Scholar]
- 28.DiFrancesco D. Serious workings of the funny current. Prog. Biophys. Mol. Biol. 2006;90:13–25. doi: 10.1016/j.pbiomolbio.2005.05.001. [DOI] [PubMed] [Google Scholar]
- 29.Fenske S., Krause S.C., Hassan S.L., Becirovic E., Auer F., Bernard R., Kupatt C., Lange P., Ziegler T., Wotjak C.T., et al. Sick sinus syndrome in HCN-1 deficient mice. Circulation. 2013;128:2585–2594. doi: 10.1161/CIRCULATIONAHA.113.003712. [DOI] [PubMed] [Google Scholar]
- 30.Brummett C.M., Hong E.K., Janda A.M., Amodeo F.S., Lydic R. Perineural dexmedetomidine added to ropivacaine for sciatic nerve block in rats prolongs the duration of analgesia by blocking the hyperpolarization-activated cation current. Anesthesiology. 2011;115:836–843. doi: 10.1097/ALN.0b013e318221fcc9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Dyachok O., Zhabyeyev P., McDonald T.E. Electroporation-induced inward current in voltage-clamped guinea pig ventricular myocytes. J. Membr. Biol. 2010;238:69–80. doi: 10.1007/s00232-010-9320-z. [DOI] [PubMed] [Google Scholar]
- 32.So E.C., Tsai K.L., Wu F.T., Hsu M.C., Wu K.C., Wu S.N. Identification of minuscule inward currents as precursors to membrane electroporation-induced currents: Real-time prediction of pore appearance. Cell. Physiol. Biochem. 2013;32:402–416. doi: 10.1159/000354447. [DOI] [PubMed] [Google Scholar]
- 33.Chiang N.J., Wu S.N., Kao C.A., Huang Y.M., Chen L.T. Stimulation of electroporation-induced inward currents in glioblastoma cell lines by the heat shock protein inhibitor AUY922. Clin. Exp. Pharmacol. Physiol. 2014;41:830–837. doi: 10.1111/1440-1681.12273. [DOI] [PubMed] [Google Scholar]
- 34.Wang M., Orwar O., Olofsson J., Weber S.G. Single-cell electroporation. Anal. Bioanal. Chem. 2010;397:3235–3248. doi: 10.1007/s00216-010-3744-2. [DOI] [PubMed] [Google Scholar]
- 35.Frandsen S.K., Gissel H., Hojman P., Tramm T., Eriksen J., Gehl J. Direct therapeutic applications of calcium electroporation to effectively induce tumor necrosis. Cancer Res. 2012;72:1336–1441. doi: 10.1158/0008-5472.CAN-11-3782. [DOI] [PubMed] [Google Scholar]
- 36.Basu A., Seth S., Chauhan A.K., Bansal N., Arora K., Mahaur A. Comparative study of tumor markers in patients with colorectal carcinoma before and after chemotherapy. Ann. Transl. Med. 2016;4:71. doi: 10.3978/j.issn.2305-5839.2016.02.02. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Huang C., Jiang Y., Duan G., Li Z., Chen L., Wang X. Effects of sequential chemotherapy of FOLFIRI/FOLFOX on the endocrine axes of ACTH-cortisol and renin-angiotensin-aldosterone. J. Neurooncol. 2012;108:485–490. doi: 10.1007/s11060-012-0845-0. [DOI] [PubMed] [Google Scholar]
- 38.Stojilkovic S.S., Tabak J., Bertram R. Ion channels and signaling in the pituitary gland. Endocr. Rev. 2010;31:845–915. doi: 10.1210/er.2010-0005. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Lu T.L., Chang W.T., Chan C.H., Wu S.N. Evidence for effective multiple K+-current inhibitions by tolvaptan, a non-peptide antagonist of vasopressin V2 receptor. Front. Pharmacol. 2019;10:76. doi: 10.3389/fphar.2019.00076. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Novella Romanelli M., Sartiani I., Masi A., Mannaioni G., Manetti D., Mugelli A., Cerbai E. HCN channels modulators: The need for selectivity. Curr. Top. Med. Chem. 2016;16:1764–1791. doi: 10.2174/1568026616999160315130832. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Song L.S., Ren G.J., Chen Z.L., Chen Z.H., Zhou Z.N., Cheng H. Electrophysiological effects of protopine in cardiac myocytes: Inhibition of multiple cation channel currents. Br. J. Pharmacol. 2000;129:893–900. doi: 10.1038/sj.bjp.0703132. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Männikö R., Pandey S., Larsson P., Elinder F. Hysteresis in the voltage dependence of HCN channels: Conversion between two modes affects pacemaker properties. J. Gen. Physiol. 2005;125:305–326. doi: 10.1085/jgp.200409130. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Fürst O., D’Avanzo N. Isoform dependent regulation of human HCN channels by cholesterol. Sci. Rep. 2015;5:14270. doi: 10.1038/srep14270. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Barthel L., Reetz O., Strauss U. Use dependent attenuation of rat HCN1-mediated Ih in intact HEK293 cells. Cell Physiol. Biochem. 2016;38:2079–2093. doi: 10.1159/000445566. [DOI] [PubMed] [Google Scholar]
- 45.Wu S.N., Huang H.C., Yeh C.C., Yang W.H., Lo Y.C. Inhibitory effect of memantine, an NMDA-receptor antagonist, on electroporation-induced inward currents in pituitary GH3 cells. Biochem. Biophys. Res. Commun. 2011;405:508–513. doi: 10.1016/j.bbrc.2011.01.066. [DOI] [PubMed] [Google Scholar]
- 46.Wu S.N., Yeh C.C., Wu P.Y., Huang H.C., Tsai K.L. Investigations into the correlation properties of membrane electroporation-induced inward currents: Prediction of pore formation. Cell Biochem. Biophys. 2012;62:211–220. doi: 10.1007/s12013-011-9284-3. [DOI] [PubMed] [Google Scholar]
- 47.Fowkes R.C., Forrest-Owen W., McArdle C.A. C-type natriuretic peptide (CNP) effects in anterior pituitary cell lines: Evidence for homologous desensitization of CNP-stimulated cGMP accumulation in αT3-1 gonadotroph-derived cells. J. Endocrinol. 2000;166:195–203. doi: 10.1677/joe.0.1660195. [DOI] [PubMed] [Google Scholar]
- 48.Jerremalm E., Wallin I., Ehrsson H. New insights into the biotransformation and pharmacokinetics of oxaliplatin. J. Pharm. Sci. 2009;98:3879–3885. doi: 10.1002/jps.21732. [DOI] [PubMed] [Google Scholar]
- 49.He C., Chen F., Li B., Hu Z. Neurophysiology of HCN channels from cellular functions to multiple regulations. Prog. Neurobiol. 2014;112:1–23. doi: 10.1016/j.pneurobio.2013.10.001. [DOI] [PubMed] [Google Scholar]
- 50.Spinelli V., Sartiani L., Mugelli A., Romanelli M.N., Cerbai E. Hyperpolarization-activated cyclic-nucleotide-gated channels: Pathophysiological, developmental, and pharmacological insights into their function in cellular excitability. Can. J. Physiol. Pharmacol. 2018;96:977–984. doi: 10.1139/cjpp-2018-0115. [DOI] [PubMed] [Google Scholar]
- 51.Nakagawa T., Kaneko S. Roles of transient receptor potential ankyrin 1 in oxaliplatin-induced peripheral neuropathy. Biol. Pharm. Bull. 2017;40:947–953. doi: 10.1248/bpb.b17-00243. [DOI] [PubMed] [Google Scholar]
- 52.Ta L.E., Espeset L., Podratz J., Windebank A.J. Neurotoxicity of oxaliplatin and cisplatin for dorsal root ganglion neurons correlates with platinum-DNA binding. Neurotoxicity. 2006;27:992–1002. doi: 10.1016/j.neuro.2006.04.010. [DOI] [PubMed] [Google Scholar]
- 53.Esser A.T., Smith K.C., Gowrishankar T.R., Vasilkoski Z., Weaver J.C. Mechanisms for the intracellular manipulation of organelles by conventional electroporation. Biophys. J. 2010;98:2506–2514. doi: 10.1016/j.bpj.2010.02.035. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 54.Scott I., Logan D.C. Mitochondrial morphology transition is an early indicator of subsequent cell death in Arabidopsis. New Phytol. 2008;177:90–101. doi: 10.1111/j.1469-8137.2007.02255.x. [DOI] [PubMed] [Google Scholar]
- 55.Canta A., Pozzi E., Carozzi V.A. Mitochondrial dysfunction in chemotherapy-induced peripheral neuropathy (CIPN) Toxics. 2015;3:198–223. doi: 10.3390/toxics3020198. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 56.Wassem M., Kaushik P., Tabassum H., Parvez S. Role of mitochondrial mechanism in chemotherapy-induced peripheral neuropathy. Curr. Drug Metab. 2018;19:47–54. doi: 10.2174/1389200219666171207121313. [DOI] [PubMed] [Google Scholar]
- 57.Kaji M., Kitazumi Y., Kano K., Shirai O. The origin of hyperpolarization based on the directional conduction of action potential using a model nerve cell system. Bioelectrochemistry. 2019;128:155–164. doi: 10.1016/j.bioelechem.2019.03.007. [DOI] [PubMed] [Google Scholar]
- 58.Chen S.W., Wu P.J., Chiang B.H. In vitro neuropeptide Y mRNA expressing model for screening essences that may affect appetite using Rolf B1.T cells. J. Agric. Food Chem. 2012;60:7824–7829. doi: 10.1021/jf302320f. [DOI] [PubMed] [Google Scholar]
- 59.So E.C., Wang Y., Yang L.Q., So K.H., Lo Y.C., Wu S.N. Multiple regulatory actions of 2-guanidine-4-methylquinazoline (GMQ), an agonist of acid-sensing ion channel type 3, on ionic currents in pituitary GH3 cells and in olfactory sensory (Rolf B1.T) neurons. Biochem. Pharmacol. 2018;151:79–88. doi: 10.1016/j.bcp.2018.02.027. [DOI] [PubMed] [Google Scholar]